Weekly Digest - August 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - August 2024
28 Aug 2024: China’s Duality Biotherapeutics Seeks IPO to Accelerate ADC Development
- Duality Biotherapeutics, a clinical-stage biotech company in China, has filed for an IPO on the Hong Kong Stock Exchange. Specializing in ADCs, the company aims to raise funds to develop its ADC pipeline
- DualityBio has developed multiple ADC platforms and currently has 12 in-house candidates, half of which are already in clinical trials. The company has also partnered with Germany’s BioNTech, BeiGene and Adcendo to enhance its ADC portfolio, with total deal values potentially exceeding $4 billion
- One of the core products, BNT323 (formerly DB-1303), is a HER2-targeted ADC for which DualityBio aims to file for accelerated FDA approval by 2025.
- Another ADC, BNT324 (formerly DB-1311), targeting the B7-H3 protein in cancers such as NSCLC and CRPC, is in Phase I/IIa trials with FDA Fast Track Designation and is also being evaluated as both a monotherapy and in combination with other treatments
